Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D

被引：0
|
作者：
Orhan Yιldιz [1 ]
Bilgehan Aygen [1 ]
Nese Demirtürk [2 ]
Tuna Demirdal [2 ]
Dilara Inan [3 ]
Taner Yιldιrmak [4 ]
Arzu Kantürk [4 ]
Ediz Tütüncü [5 ]
Hepatitis B Study Group
机构：
[1] Department of Infectious Diseases and Clinical Microbiology, Medical School of Erciyes University
[2] Department of Infectious Diseases and Clinical Microbiology, Medical School of Kocatepe University
[3] Department of Infectious Diseases and Clinical Microbiology, Medical School of Akdeniz University  4. Okmeydani Training and Research Hospital of the Ministry of Health, 34384 Istanbul, Turkey 
来源：
World Journal of Gastroenterology | 2011年 / 17卷 / 45期
关键词：
Hepatitis B virus; Genotype; Resistance; Lamivudine; Tyrosine-methionine-aspartate-aspartate mutation;
D O I：
暂无
中图分类号：
R512.62 [];
学科分类号：
100401 ;
摘要：
AIM: To determine the distribution of viral genotypes for primary or acquired lamivudine resistance. METHODS: A total of 283 patients with chronic hepatitis B virus (HBV) infection (245 patients with chronic hepatitis B and 38 inactive hepatitis B surface antigen carriers) were included in the study. The HBV geno-type was determined by using quantitative real-time polymerase chain reaction and sequence analysis, and tyrosine-methionine-aspartate-aspartate (YMDD) motif mutations were determined using the reverse transcriptase hybridization method. RESULTS: Lamivudine resistance was determined in a total of 25 (10.7%) chronic hepatitis B patients. Eight subjects (4%) had primary resistance to lamivudine, and 17 (53.1%) had secondary resistance to lamivudine. Genotype D, which was isolated from 267 of the patients with chronic HBV infection, was the dominant genotype in Turkey. CONCLUSION: Identification of YMDD motif mutations should have a positive impact on the selection of proper antiviral medication for patients, even for those who are nucleoside nave.
引用
收藏
页码：4987 / 4992
页数：6
相关论文
共 50 条
  • [31] Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine
    Amini-Bavil-Olyaee, Samad
    Hosseini, Sayed Younes
    Sabahi, Farzaneh
    Alavian, Seyed-Moayed
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 (01) : 83 - 87
  • [32] Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern
    Inoue, J.
    Ueno, Y.
    Wakui, Y.
    Niitsuma, H.
    Fukushima, K.
    Yamagiwa, Y.
    Shiina, M.
    Kondo, Y.
    Kakazu, E.
    Tamai, K.
    Obara, N.
    Iwasaki, T.
    Shimosegawa, T.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2011, 18 (03) : 206 - 215
  • [33] Hepatitis B virus surface gene mutations are often associated with lamivudine resistance mutations in the absence of treatment with hepatitis B immunoglobulin (HBIG)
    Barnes, E
    Mathou, N
    Qattan, I
    Brown, D
    Bloor, S
    Clarke, B
    Dhillon, A
    Dusheiko, G
    [J]. GUT, 2003, 52 (05)
  • [34] Influence of hepatitis B virus sequence variation, genotype and HBeAg status on the selection of lamivudine resistance
    Desmond, PV
    Ayres, A
    Warner, N
    Thompson, G
    Bartholomeusz, A
    Yeun, L
    Locarnini, S
    Kuay, J
    Luk, E
    Bell, S
    Chen, R
    [J]. HEPATOLOGY, 2002, 36 (04) : 640A - 640A
  • [35] Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine
    Matsuda, M
    Suzuki, F
    Suzuki, Y
    Tsubota, A
    Akuta, N
    Hosaka, T
    Someya, T
    Kobayashi, M
    Saitoh, S
    Arase, Y
    Satoh, J
    Takagi, K
    Kobayashi, M
    Ikeda, K
    Kumada, H
    [J]. JOURNAL OF GASTROENTEROLOGY, 2004, 39 (01) : 34 - 40
  • [36] Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine
    Marie Matsuda
    Fumitaka Suzuki
    Yoshiyuki Suzuki
    Akihito Tsubota
    Norio Akuta
    Tetsuya Hosaka
    Takashi Someya
    Masahiro Kobayashi
    Satoshi Saitoh
    Yasuji Arase
    Junko Satoh
    Kimiko Takagi
    Mariko Kobayashi
    Kenji Ikeda
    Hiromitsu Kumada
    [J]. Journal of Gastroenterology, 2004, 39 : 34 - 40
  • [37] Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B
    Ogata, N
    Fujii, K
    Takigawa, S
    Nomoto, M
    Ichida, T
    Asakura, H
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1999, 59 (03) : 270 - 276
  • [38] Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay
    Libbrecht, Evelien
    Doutreloigne, Joke
    Van De Velde, Hilde
    Yuen, Man-Fung
    Lai, Ching-Lung
    Shapiro, Fred
    Sablon, Erwin
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (12) : 3935 - 3941
  • [39] Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
    Allen, MI
    Deslauriers, M
    Andrews, CW
    Tipples, GA
    Walters, KA
    Tyrrell, DLJ
    Brown, N
    Condreay, LD
    [J]. HEPATOLOGY, 1998, 27 (06) : 1670 - 1677
  • [40] Predominance of Hepatitis B Virus Genotype A Among Treated HIV Infected Patients Experiencing High Hepatitis B Virus Drug Resistance in Nairobi, Kenya
    Mabeya, Sepha Nyatichi
    Ngugi, Caroline
    Lihana, Raphael Wekesa
    Khamadi, Samoel Ashimosi
    Nyamache, Anthony Kebira
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2017, 33 (09) : 966 - 969
12345